

Supplemental Table 1 Brief chronology of key clinical events in this case

| Time before and after CAR T cell therapy | Date | Key events |
|---|--------------------------|--|
| -8.5 months | 09/14/2018 | Diagnosis of DLBCL, GCB |
| -8 months to -3 months | 09/19/2018 to 01/22/2019 | 6 cycles of <i>R-CHOP</i> (response evaluation: PD) |
| -2.5 months | 02/19/2019 | 1 cycle of <i>R-ESHAP</i> (response evaluation: PD) |
| -3 weeks | 03/15/2019 | 1 cycle of <i>ICE</i> |
| -9 days to -1 day | 04/25/2019 to 05/01/2019 | Lymphocytes collection and myeloablative chemotherapy regimen (<i>BEAM</i>) |
| 0 day | 05/02/2019 | <i>ASCT</i> |
| +6 day | 05/08/2019 | <i>Murine anti-CD22 CAR T cell therapy</i> (2.77 x 10 ⁶ cells/kg) |
| +7 day | 05/09/2019 | <i>Murine anti-CD19 CAR T cell therapy</i> (2.50 x 10 ⁶ cells/kg) |
| +1.5 month | 06/27/2019 | Response evaluation by CT : SD |
| +2 months | 07/12/2019 | Response evaluation by PET/CT : PD |
| +2.5 months to +3 months | 07/19/2019 to 08/11/2019 | <i>Sintilimab Injection</i> (an anti PD-1 antibody) plus novel immunotherapeutic drugs (<i>rituximab, chidamide, bortezomib and dexamethasone</i>) |
| +5 months | 10/02/2019 to 10/06/2019 | Lymphodepleting chemotherapy regimen (<i>FC</i>) and <i>human anti-BCMA CAR T cell therapy</i> |
| +6 months | 11/05/2019 | Response evaluation by PET/CT : PD |